Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue International Journal of Tuberculosis and Lung Disease Année : 2015

Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance

Résumé

Background: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (TB) constitute a major public health concern. The objective was to determine the timing of pncA mutations that confer pyrazinamide (PZA) resistance in relation to mutations conferring resistance to isoniazid (INH) and rifampicin (RMP). For this goal, isolates from two major urban centres—Paris (101 strains) and Shanghai (171 strains)—were investigated for the association of pncA mutations with resistance to drugs other than PZA. The proportion of pncA mutations found in INH-monoresistant strains was not increased. In sum, pncA mutations associated with PZA resistance were found almost exclusively in MDR-TB strains, underlining the importance of determining PZA resistance when treating MDR- or XDR-TB.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

pasteur-01185256 , version 1 (19-08-2015)

Identifiants

Citer

Amel Kevin Alame-Emane, Peng Xu, C Pierre-Audigier, Véronique Cadet-Daniel, X Shen, et al.. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. International Journal of Tuberculosis and Lung Disease, 2015, 19 (6), pp.679-84. ⟨10.5588/ijtld.14.0768⟩. ⟨pasteur-01185256⟩

Collections

PASTEUR RIIP
125 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More